Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Location
Three Bala Plaza East. Suite 506, Bala Cynwyd, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 % -54.5%
Debt-to-equity 23.1 % +114%
Return On Equity -91.8 % -156%
Return On Assets -74.6 % -130%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.6M shares +34.1%
Common Stock, Shares, Outstanding 85.6M shares +34.1%
Entity Public Float 314M USD
Common Stock, Value, Issued 86K USD +34.4%
Weighted Average Number of Shares Outstanding, Basic 78.3M shares +22.8%
Weighted Average Number of Shares Outstanding, Diluted 78.3M shares +22.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 122M USD +113%
General and Administrative Expense 18.2M USD +9.73%
Operating Income (Loss) -140M USD -89.5%
Nonoperating Income (Expense) 7.77M USD -13.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -132M USD -104%
Earnings Per Share, Basic -1 USD/shares -71.1%
Earnings Per Share, Diluted -1 USD/shares -71.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 90.1M USD +157%
Cash, Cash Equivalents, and Short-term Investments 175M USD -13.9%
Assets, Current 183M USD -14.1%
Property, Plant and Equipment, Net 709K USD -8.99%
Operating Lease, Right-of-Use Asset 2.27M USD -25%
Other Assets, Noncurrent 542K USD -12.7%
Assets 187M USD -14.5%
Accounts Payable, Current 11.1M USD +558%
Employee-related Liabilities, Current 3.22M USD +35.5%
Accrued Liabilities, Current 32.9M USD +142%
Liabilities, Current 45.1M USD +177%
Operating Lease, Liability, Noncurrent 3.2M USD -26.3%
Liabilities 48.3M USD +134%
Accumulated Other Comprehensive Income (Loss), Net of Tax 66K USD -81.6%
Retained Earnings (Accumulated Deficit) -372M USD -54.9%
Stockholders' Equity Attributable to Parent 139M USD -29.9%
Liabilities and Equity 187M USD -14.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.5M USD -155%
Net Cash Provided by (Used in) Financing Activities 162M USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 85.6M shares +34.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -115%
Deferred Tax Assets, Valuation Allowance 173M USD +22%
Deferred Tax Assets, Gross 174M USD +21.9%
Operating Lease, Liability 4.35M USD -18.9%
Depreciation 88K USD +10%
Payments to Acquire Property, Plant, and Equipment 49K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -132M USD -105%
Lessee, Operating Lease, Liability, to be Paid 5.29M USD -22.4%
Property, Plant and Equipment, Gross 2.52M USD +12%
Operating Lease, Liability, Current 1.15M USD +12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.27M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.48M USD -4.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 941K USD -35.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.19M USD -6.24%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 959K USD -19.3%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7.86M USD -5.39%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%